Get started
Author

Andrea K. McCollum

Observed names: A. K. McCollum, A. McCollum, Andrea McCollum, Andrea K. McCollum
OpenAlex ID: A5001387618
Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism
2006 · Andrea K. McCollum, Cynthia J. TenEyck, et al. · Cancer Research · 157
PDF
A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer
2006 · Grzegorz S. Nowakowski, Andrea K. McCollum, et al. · Clinical Cancer Research · 113
Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation
2007 · Chunrong Yu, Bret B. Friday, et al. · Clinical Cancer Research · 77
P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2008 · Andrea K. McCollum, Cynthia J. TenEyck, et al. · Cancer Research · 76
PDF
Cisplatin abrogates the geldanamycin-induced heat shock response
2008 · Andrea K. McCollum, Kara B. Lukasiewicz, et al. · Molecular Cancer Therapeutics · 54
PDF
Caught in the middle: the role of Bag3 in disease
2009 · Andrea K. McCollum, Giovanna Casagrande, et al. · Biochemical Journal · 51
A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer
2004 · C. Erlichman, D. Toft, et al. · Journal of Clinical Oncology · 16
A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients
2004 · P. Haluska, D. O. Toft, et al. · Journal of Clinical Oncology · 10
Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin.
2011 · J. L. Hays, G. Kim, et al. · Journal of Clinical Oncology · 3
Abstract 2032: A novel function of WW domain binding protein 2 (WBP2) in regulating cytoskeletal function and cellular division through binding to co-chaperone BAG3
2012 · Andrea K. McCollum, Mathew G. Angelos, et al. · Cancer Research · 2
Supplementary Table 1 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
PDF
Supplementary Figure Legends 1-2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Data from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Supplementary Figure 1 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
PDF
Supplementary Figure 2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Supplementary Figure 1 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Supplementary Figure 2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
PDF
Supplementary Table 1 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Data from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
Supplementary Figure Legends 1-2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
2023 · Andrea K. McCollum, Cynthia J. TenEyck, et al.
PDF
Abstract LB-190: Novel cell cycle regulation through the WW-domain of the co-chaperone BAG3
2011 · Mathew G. Angelos, Elise C. Kohn, et al. · Cancer Research
Works count: 21
Citation count: 559
H-index: 8
I10-index: 8
Year
Topic
Type